Revive Therapeutics is an Interesting COVID-19 Treatment Speculation

Published:

Revive Therapeutics Ltd. (CSE:RVV) is using an existing drug to study the prevention of lung injury caused by the influenza virus

SmallCapPower | April 6, 2020: Ever since the COVID-19 outbreak began to dominate the news globally, publicly-traded companies that have reportedly been working on a potential vaccine, testing or other treatment method have seen their stock prices surge. While the majority of these rallies will almost certainly be short lived, recent investor interest in Revive Therapeutics Ltd. (CSE:RVV) might be just getting started.

Win Big With Our Small Cap Picks

 

Revive Therapeutics is a specialty life sciences company focused on repurposing drugs for rare disorders and infectious diseases. While Revive has previously worked in the development of Psiliocybin and Cannabidiol therapeutics for various central nervous system and inflammatory disorders, it is its clinical development advancement of the drug Bucillamine for infectious diseases, including COVID-19, that has caught the market’s attention.

Bucillamine has a proven safety profile and has been prescribed for arthritis in Japan and South Korea for more than 30 years. In the past, Revive Therapeutics has explored the use of Bucillamine in the treatment of acute gout flares in a Phase 2 study in the U.S. under its Investigational New Drug (IND) application that was granted and accepted by the U.S. Food and Drug Administration (FDA). Additionally, the Company has explored the use of Bucillamine in the treatment of cystinuria, where it has received FDA orphan drug status and its IND was also accepted by the FDA to conduct a Phase 2 study in the United States.

Novel antivirals for influenza treatment have been limited by poor oral bioavailability and lack of efficacy when not delivered early. This is because these drugs mostly act to prevent the early processes of virus binding to cells or viral replication. Thiols, particularly N-acetylcysteine (NAC), with antioxidant and reducing activity have been investigated as effective therapies that inhibits the potential for influenza to cause severe disease. Studies in human cells and animal models have shown that NAC works to prevent acute lung injury caused by influenza virus infection through inhibition of Reactive oxygen species (ROS) generation that aggravates destructive inflammation.

Revive Therapeutics asserts that Bucillamine is 16 times more potent than NAC in preventing acute lung injury caused by influenza virus, as it has shown superior function in restoring glutathione, an antioxidant in plants, animals, and fungi. Revive is advancing towards FDA Phase 2 Bucillamine clinical study for treating the effects of COVID-19.

Revive Therapeutics, while still highly speculative, has positioned itself in the COVID-19 arena. Sovereign nations are scrambling and loosening regulatory reins as they seek to find options, therapies and indeed a panacea to halt a pandemic that has literally caused the entire planet to pause. Revive is proposing a potential solution to an outbreak that could result in a stock-price breakout.

To read our full disclosure, please click on the button below:

Related articles

Recent articles